This investment fund aims to mirror the performance, prior to fees and expenses, of a specific benchmark index. This index is designed to track companies worldwide that are poised to generate revenue from addressing or serving the obese population. These companies span various sectors, including biotechnology, pharmaceuticals, healthcare, and medical device firms primarily focused on obesity and its related health conditions. The index also includes businesses that provide weight loss programs, dietary supplements, or specialize in plus-sized apparel. The fund allocates a significant portion—at least 80% of its net assets—to the stocks that make up the Solactive Obesity Index. It is important to note that this is a non-diversified investment vehicle.


Net sales
Gross margin
Net income